How many investments has Proto Axiom made?

Proto Axiom has 9 tracked investments, including 1 dated in the last 24 months.

What stage does Proto Axiom invest at?

Proto Axiom invests at the Pre-Seed, Seed stages.

What sectors does Proto Axiom focus on?

Proto Axiom focuses on Biotech, Deep Tech, FemTech, Healthtech, Medical Devices.

Where is Proto Axiom located?

Proto Axiom is headquartered in Sydney, AU.

Does Proto Axiom lead rounds?

Yes, Proto Axiom leads investment rounds.

Proto Axiom

Venture studio

Sydney · Pre-Seed–Seed · 28 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Proto Axiom

Each arrow is one introduction. Sign up to fill in the first one.

394 people can intro you to Laura

Ask Sam Almaliki to introduce you to Laura Wimberger

You →Sam · together at University of Wollongong →Laura

266 people can intro you to Richard

Ask Jamie Chen to introduce you to Richard Wang

You →Jamie · together at ResMed →Richard

262 people can intro you to Anthony

Ask Sam Okafor to introduce you to Anthony Liveris

You →Sam · together at St Vincent's Curran Foundation →Anthony

Hugh McGonagle212 people can intro you
Charlie Selth208 people can intro you
Lindsay Wu185 people can intro you

Your email: who you already know at Proto Axiom, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Proto Axiom team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Proto Axiom operates as a venture studio, building the companies it invests in rather than solely backing external founders. Based in Sydney and established in 2021, the firm centers its work on Australian science combined with what it describes as pharma-grade execution. Its associated initiatives, including a Challenger Summit and a Women's Health Foundry, suggest a focus on science-driven, health-related company creation.

Invests inBiotech Deep Tech FemTech Healthtech Medical Devices Asia-Pacific Australia Sydney

Source: firm website, verified Aug 3, 2026.

Leave your own feedback

Stage

Pre-Seed–Seed

Sydney, AU

Leads rounds

Leads

Instruments

Equity

Founded

2021

Last 12 months

1 investment

Tracked investments

Team · 28 people

from the firm's website

Anthony Liveris· Chief Executive Officer· Sydney, New South Wales, Australiain

Founding CEO of Proto Axiom, building it into a company-creation platform focused on Australian science. Previously co-founded Applecart, a New York data and technology company that received a US$100M investment from Blackstone Growth.

Tony Haddad· Operating Partner

Operating Partner focused on operations.

Anand Gautum· Chair, Strategic Advisors

Chair of Strategic Advisors with experience at Pfizer and Novo Nordisk.

Annalisa Jenkins· Non-Executive Director

Non-Executive Director, former CEO of Dimension Therapeutics and former Head of Global Drug Development at Merck Serono, contributing to development of over 30 therapeutics.

Brian Ledwith· Chair, Scientific Advisory Board

Chair of the Scientific Advisory Board with over 30 years in vaccines and gene therapy.

Charlie Selth· Chief of Staff· Sydney, New South Wales, Australiain

Chief of Staff focused on strategy.

Gavin MacLaren· Chair· Australiain

Board chairman with over 20 years as a lawyer, including a decade in Asia. Named an Innovative Leader in the 2020 FT Innovative Lawyers Awards Asia Pacific.

Hugh McGonagle· Chief Operating Officer· Greater Sydney Areain

Chief Operating Officer with a legal and risk background.

Iain Mackay· Strategic Advisor

Strategic Advisor and former CFO of GSK and HSBC.

James Rush· Scientific Advisor

Scientific Advisor with experience at Novartis and Spica Therapeutics.

John Roach· Head of Finance· Greater Sydney Areain

Head of Finance with finance and pharma operations experience.

Kathy Connell· Non-Executive Director

Non-Executive Director with two decades in life-sciences business development and investment at Johnson & Johnson and Sanofi, deploying over US$1B across ANZ in licensing and acquisitions.

Laura Wimberger· Investment Associate· Greater Sydney Areain

Investment Associate with a PhD.

Lawrence Gozlan· Strategic Advisor

Strategic Advisor and CIO of Scientia Capital.

Lindsay Wu· Chief Science Officer· Greater Sydney Areain

Chief Science Officer focused on drug development and translation.

Marina Naidion· Business Manager· North Sydney, New South Wales, Australiain

Business Manager.

Michael Sierra· Scientific Advisor

Scientific Advisor with experience at LEO Pharma and GlaxoSmithKline.

Michelle Burke· Strategic Advisor

Strategic Advisor associated with AusBiotech and PBAC.

Nicholas Hunt· Entrepreneur in Residence· Sydney, New South Wales, Australiain

Entrepreneur in Residence with a founder-operator background in nanomedicine.

Peter Devine· Non-Executive Director

Non-Executive Director who spent 20 years as CEO of Uniseed, the A$200M partnership between Australian research institutions and UniSuper, and led multiple biotech exits.

Richard Wang· Science Analyst· Australiain

Science Analyst with a PhD.

Rob McInnes· Strategic Advisor

Strategic Advisor specializing in IP advisory, associated with Spruson & Ferguson.

Russell Basser· Scientific Advisor

Scientific Advisor with experience at CSL Ltd and Starpharma.

Sally Bennett· Non-Executive Director

Non-Executive Director and Senior Advisor at Catalio Capital Management, with over 25 years across medicine, equity capital markets and life-sciences investment management.

Sara Althari· Scientific Advisor

Scientific Advisor associated with the Saudi Ministry of Investment.

Tom Harley· Non-Executive Director

Non-Executive Director and Managing Director of Dragoman. Former President of Corporate Development at BHP and former Non-Executive Chairman of Dow Chemical Australia.

Tristan Edwards· Non-Executive Director

Non-Executive Director, co-founder and first CEO of Boston-based Life Biosciences, with 18 years in global funds management at Goldman Sachs Asset Management and Brevan Howard.

William Marshall· Scientific Advisor

Scientific Advisor affiliated with UMass Medical and Harvard Medical.

Founder mafia

2 people who came through Proto Axiom went on to found or lead other companies.

Anthony LiverisChief Executive OfficerFounded Applecart Lindsay WuChief Science OfficerFounded JumpStart Fertility

What they invest in

from 4 of 9 portfolio companies

Biotech ×3Deep Tech ×2Healthtech ×2Medical Devices ×1New Materials ×1

HQs:United States×2Australia×1

Investments · 9 tracked

founders shown can be your intro path

By year:2026 · 1 2017 · 12 dated

AdvanCell Isotopesadvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)in Aaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life Sciences Catalio Capital Management, LP Sanofi Ventures SV Health Investors Tenmile Abingworth +2 more

Flo Axiomfloaxiom.com

Floaxiom develops NanoSurface, a biologically manufactured affinity nanoparticle platform for antibody (mAb) purification, offering a chromatography-free alternative to protein A resin columns and membrane systems.

BiotechDeep TechNew Materials

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Amazing GutCellutechEndo AxiomHerikinJumpStart FertilityOnyx AxiomSWAN Genomics

Portfolio news

latest coverage across their companies

AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360

AdvanCell Isotopes · intelligence360.news · Aug 4, 2026

Frequently asked questions

How many investments has Proto Axiom made?: Proto Axiom has 9 tracked investments, including 1 dated in the last 24 months.
What stage does Proto Axiom invest at?: Proto Axiom invests at the Pre-Seed, Seed stages.
What sectors does Proto Axiom focus on?: Proto Axiom focuses on Biotech, Deep Tech, FemTech, Healthtech, Medical Devices.
Where is Proto Axiom located?: Proto Axiom is headquartered in Sydney, AU.
Does Proto Axiom lead rounds?: Yes, Proto Axiom leads investment rounds.
Who does Proto Axiom co-invest with?: Proto Axiom most often shares deals with Bain Capital Life Sciences, Catalio Capital Management, LP, Sanofi Ventures, among 5 tracked co-investors.

Similar investors

Future Positive Capital

Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.

Sv Tech Ventures, Inc.

SV Tech Ventures is a Palo Alto-based venture capital firm investing in early-stage, high-tech startups, offering hands-on support with strategy, product, fundraising, and hiring across its funds.

Overwater Ventures Llc

Overwater Ventures is an early-stage venture firm that partners with pre-seed and seed stage founders working on large-scale problems, offering hands-on support across launch strategy, go-to-market, fundraising, and marketing.